Skip to main content

ASH Highlights

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Multiple Myeloma

Dual-Targeted CAR T-Cell Therapy Leads to Very High Response Rates in Relapsed or Refractory Multiple Myeloma

Meeting Highlights

ASH Highlights

Triplet Therapy with Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Meeting Highlights

ASH Highlights

Resistance to Acalabrutinib in Chronic Lymphocytic Leukemia Is Mediated Predominantly by BTK Mutations

Meeting Highlights

ASH Highlights

Ibrutinib + Venetoclax for First-Line Treatment of CLL: Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Meeting Highlights

ASH Highlights

Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia

Meeting Highlights

ASH Highlights

Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial

Meeting Highlights

ASH Highlights

Checkpoint Inhibition Consolidation Therapy Promising in High-Risk Hematologic Malignancies

Charles Bankhead

Charles Bankhead, Medical Writer

Meeting Highlights

ASH Highlights

MURANO: Venetoclax-Rituximab at Fixed Duration Beats Chemoimmunotherapy in Relapsed/Refractory CLL

Phoebe Starr, Medical Writer

Meeting Highlights

ASH Highlights

Researchers Identify First Mutation to Explain Resistance to Venetoclax

Phoebe Starr, Medical Writer

Meeting Highlights

ASH Highlights, Immunotherapy

Checkpoint Inhibitor a New Approach to Jump-Start a Waning Response to CAR T-Cell Therapy

Phoebe Starr, Medical Writer

3
4
5
6
7

Page 6 of 7
Results 51 - 60 of 70